PLUS THERAPEUTICS, INC. — Director's Dealing 2016

Jun 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2016-06-15

Reporting Person: Hawkins Richard J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-15	Common Stock	X	3356	—	Acquired	8435	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-15	Subscription Rights (Right to Buy)	$2.55	X	3356	Disposed	2016-06-10	See Footnote (3356)	Direct
2016-06-15	Warrants (Right to Buy)	$3.06	X	1678	Acquired	2018-12-14	Common Stock (1678)	Direct

Footnotes

F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $2.55.

F2: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $3.06 from the date of issuance through December 14, 2018.